Kaleido Biosciences, Inc. Common Stock
KLDO
KLDO was delisted on the 14th of April, 2022.
71 hedge funds and large institutions have $258M invested in Kaleido Biosciences, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 10 reducing their positions, and 13 closing their positions.
190% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 10
0% more funds holding
Funds holding: 71 → 71 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
7% less capital invested
Capital invested by funds: $278M → $258M (-$20.1M)
37% less call options, than puts
Call options by funds: $325K | Put options by funds: $513K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$1.24M |
| 2 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$751K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$510K |
| 4 |
BlackRock
New York
|
+$458K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$293K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$823K |
| 2 |
Renaissance Technologies
New York
|
-$438K |
| 3 |
Two Sigma Advisers
New York
|
-$362K |
| 4 |
Two Sigma Investments
New York
|
-$300K |
| 5 |
Millennium Management
New York
|
-$111K |
KLDO Hedge Fund Activity: Q2 2021 in Review
71 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q2 2021, worth a combined $258M — down 7.2% from $278M a quarter earlier.
Fund positioning in KLDO was balanced in Q2 2021: 13 funds opened new positions, 13 closed out, 29 added to existing stakes and 10 trimmed.
The largest buyer was State Street, adding an estimated $1.24M. The largest seller was Raymond James & Associates, exiting entirely with an estimated $823K sold.
- 71 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $258M of Kaleido Biosciences, Inc. Common Stock stock for Q2 2021, down 7.2% quarter-over-quarter.
- 13 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q2 2021 and 13 closed out, a net change of 0 holders.
- The largest Kaleido Biosciences, Inc. Common Stock buyer in Q2 2021 was State Street, an estimated $1.24M added.
- The largest Kaleido Biosciences, Inc. Common Stock seller in Q2 2021 was Raymond James & Associates, an estimated $823K sold.
Based on aggregated 13F filings for Q2 2021.